What is Dyadic Applied BioSolutions?
Dyadic Applied BioSolutions, formerly Dyadic International, is a global biotechnology firm established in 1979. The company has developed a proprietary gene expression platform utilizing the fungus Thermothelomyces heterothallica, known as C1. This innovative system is engineered to facilitate the cost-effective development and production of proteins essential for biologic vaccines and drugs. The C1 platform is designed to accelerate the development timeline, reduce manufacturing expenses, and enhance the performance of a wide array of therapeutic products, including virus-like particles, antigens, and monoclonal antibodies.
Dyadic's business model centers on research and development collaborations and strategic licensing agreements, aiming to maximize the impact of its technologies within the biopharmaceutical manufacturing landscape. The company's core mission is to streamline the path to market for biologic products, thereby improving global healthcare accessibility through its unique fungal expression system.
How much funding has Dyadic Applied BioSolutions raised?
Dyadic Applied BioSolutions has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Dyadic Applied BioSolutions?
With the recent strategic investment, Dyadic Applied BioSolutions is poised for significant expansion and acceleration of its development pipeline. The substantial capital infusion, indicative of a large-scale late-stage funding round, suggests the company is moving towards commercialization or scaling its manufacturing capabilities. This backing will likely fuel further research into novel protein therapeutics and biopharmaceuticals, potentially leading to new drug discoveries and more efficient production methods.
The company's focus on R&D collaborations and licensing is expected to intensify, leveraging the C1 platform's advantages to forge new partnerships. Dyadic's strategic direction points towards solidifying its position as a key player in biopharmaceutical manufacturing, aiming to deliver cost-effective and high-performance biologic products to a global market.
